Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients

Breast Cancer Research and Treatment

Volumn 112, Issue 1, 2008, Pages 89-98

  Fasching, Peter Andreas ^a   Loehberg, Christian R ^a   Strissel, Pamela L ^a   Lux, Michael P ^a   Bani, Mayada R ^a   Schrauder, Michael ^a   Geiler, Sonja ^a   Ringleff, Kerstin ^a   Oeser, Sonja ^a   Weihbrecht, Sebastian ^a   Schulz Wendtland, Rüdiger ^a   Hartmann, Arndt ^b   Beckmann, Matthias W ^a   Strick, Reiner ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Aromatase; Breast cancer; CYP19A1; HER2; Prognosis; Single nucleotide polymorphism

Indexed keywords

AROMATASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENOTYPE; GERMANY; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; AROMATASE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 52949088650     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9822-2     Document Type: Article

References (40)

1. JD Yager NE Davidson 2006 Estrogen carcinogenesis in breast cancer N Engl J Med 354 270 282
2. M Clemons P Goss 2001 Estrogen and the risk of breast cancer N Engl J Med 344 276 285
3. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
4. RC Coombes E Hall LJ Gibson 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092
5. M Baum AU Budzar J Cuzick 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139
6. M Baum A Buzdar J Cuzick 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 1802 1810
7. R Jakesz W Jonat M Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462
8. PE Goss JN Ingle S Martino 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 1262 1271
9. PE Goss JN Ingle S Martino 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793 1802
10. B Thurlimann A Keshaviah AS Coates 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757
11. ER Simpson MS Mahendroo GD Means 1994 Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis Endocr Rev 15 342 355
12. LM Berstein EN Imyanitov AJ Kovalevskij 2004 CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity Cancer Lett 207 191 196
13. JS O'Neill RA Elton WR Miller 1988 Aromatase activity in adipose tissue from breast quadrants: a link with tumour site Br Med J (Clin Res Ed) 296 741 743
14. K Zeitoun K Takayama MD Michael 1999 Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element Mol Endocrinol 13 239 253
15. VR Agarwal SE Bulun M Leitch 1996 Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients J Clin Endocrinol Metab 81 3843 3849
16. P Acien I Velasco M Gutierrez 2007 Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings Fertil Steril 88 32 38
17. N Pathirage LA Di Nezza LA Salmonsen 2006 Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer Fertil Steril 86 469 472
18. J Lu H Li D Cao 2007 Clinical significance of aromatase protein expression in axillary node negative breast cancer J Cancer Res Clin Oncol 133 401 409
19. FS Ribeiro LM de Amorim T de Almeida Simao 2006 CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women Toxicol Lett 164 90 95
20. MN Okobia CH Bunker JM Zmuda 2006 Simple tandem repeat (TTTA)n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women J Carcinog 5 12
21. VN Kristensen TI Andersen A Lindblom 1998 A rare CYP19 (aromatase) variant may increase the risk of breast cancer Pharmacogenetics 8 43 48
22. SW Baxter DY Choong DM Eccles 2001 Polymorphic variation in CYP19 and the risk of breast cancer Carcinogenesis 22 347 349
23. Y Miyoshi A Ando S Hasegawa 2003 Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk Eur J Cancer 39 2531 2537
24. NM Probst-Hensch SA Ingles AT Diep 1999 Aromatase and breast cancer susceptibility Endocr Relat Cancer 6 165 173
25. B Thyagarajan M Brott P Mink 2004 CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study Cancer Lett 207 183 189
26. DA Ralph LP Zhao CE Aston 2007 Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk Cancer 109 1940 1948
27. JE Olson JN Ingle CX Ma 2007 A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches Breast Cancer Res Treat 102 237 247
28. VN Kristensen N Harada N Yoshimura 2000 Genetic variants of CYP19 (aromatase) and breast cancer risk Oncogene 19 1329 1333
29. CA Haiman SE Hankinson D Spiegelman 2002 No association between a single nucleotide polymorphism in CYP19 and breast cancer risk Cancer Epidemiol Biomarkers Prev 11 215 216
30. CX Ma AA Adjei OE Salavaggione 2005 Human aromatase: gene resequencing and functional genomics Cancer Res 65 11071 11082
31. AM Dunning M Dowsett CS Healey 2004 Polymorphisms associated with circulating sex hormone levels in postmenopausal women J Natl Cancer Inst 96 936 945
32. SS Tworoger J Chubak EJ Aiello 2004 Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women Cancer Epidemiol Biomarkers Prev 13 94 101
33. CA Haiman L Dossus VW Setiawan 2007 Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women Cancer Res 67 1893 1897
34. Y Guo DH Xiong TL Yang 2006 Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females Hum Mol Genet 15 2401 2408
35. JR Long N Kataoka XO Shu 2006 Genetic polymorphisms of the CYP19A1 gene and breast cancer survival Cancer Epidemiol Biomarkers Prev 15 2115 2122
36. RW Blamey L Cataliotti 2006 EUSOMA accreditation of breast units Eur J Cancer 42 1331 1337
37. EW Elston IO Ellis 1993 Method for grading breast cancer J Clin Pathol 46 189 190
38. AC Wolff ME Hammond JN Schwartz 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145
39. Talbott KE, Gammon MD, Kibriya MG et al (2007) A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat. doi: 10.1007/s10549-007-9794-2
40. L Zhu LW Chow WT Loo 2004 Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial Clin Cancer Res 10 4639 4644